554 related articles for article (PubMed ID: 26525199)
1. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
3. Treatment course of steroid-dependent nephrotic syndrome: emphasized on treatment effect.
Chen SY; Wu CY; Tsai IJ; Tsau YK
Nephrology (Carlton); 2010 Apr; 15(3):336-9. PubMed ID: 20470303
[TBL] [Abstract][Full Text] [Related]
4. Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome.
Kari JA; Alhasan KA; Albanna AS; Safdar OY; Shalaby MA; Böckenhauer D; El-Desoky SM
Pediatr Nephrol; 2020 Aug; 35(8):1445-1453. PubMed ID: 32337638
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY; Yu ELM; Angeletti A; Arslan Z; Basu B; Boyer O; Chan CY; Colucci M; Dorval G; Dossier C; Drovandi S; Ghiggeri GM; Gipson DS; Hamada R; Hogan J; Ishikura K; Kamei K; Kemper MJ; Ma AL; Parekh RS; Radhakrishnan S; Saini P; Shen Q; Sinha R; Subun C; Teo S; Vivarelli M; Webb H; Xu H; Yap HK; Tullus K
J Am Soc Nephrol; 2022 Jun; 33(6):1193-1207. PubMed ID: 35354600
[TBL] [Abstract][Full Text] [Related]
8. Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?
Fujinaga S; Mizutani A
Clin Exp Nephrol; 2020 Dec; 24(12):1187-1188. PubMed ID: 32728924
[No Abstract] [Full Text] [Related]
9. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
Iijima K; Sako M; Kamei K; Nozu K
Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
Taşdemir M; Canpolat N; Yıldız N; Özçelik G; Benzer M; Saygılı SK; Özkayin EN; Türkkan ÖN; Balat A; Candan C; Çelakıl M; Yavuz S; Akıncı N; Göknar N; Akgün C; Tülpar S; Alpay H; Sever FL; Bilge İ
Turk J Med Sci; 2021 Aug; 51(4):1781-1790. PubMed ID: 33581711
[TBL] [Abstract][Full Text] [Related]
12. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children.
Larkins N; Kim S; Craig J; Hodson E
Arch Dis Child; 2016 Apr; 101(4):404-8. PubMed ID: 26289063
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials.
Tan L; Li S; Yang H; Zou Q; Wan J; Li Q
Medicine (Baltimore); 2019 May; 98(22):e15927. PubMed ID: 31145359
[TBL] [Abstract][Full Text] [Related]
14. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
Wu B; Mao J; Shen H; Fu H; Wang J; Liu A; Gu W; Shu Q; Du L
Nephrology (Carlton); 2015 Jan; 20(1):18-24. PubMed ID: 25312783
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain.
DaSilva I; Huerta A; Quintana L; Redondo B; Iglesias E; Draibe J; Praga M; Ballarín J; Díaz-Encarnación M;
BioDrugs; 2017 Jun; 31(3):239-249. PubMed ID: 28534103
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab.
Kamei K; Ogura M; Sato M; Sako M; Iijima K; Ito S
Pediatr Nephrol; 2016 Jan; 31(1):89-95. PubMed ID: 26341251
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.
Mathew G; Sinha A; Ahmed A; Grewal N; Khandelwal P; Hari P; Bagga A
Pediatr Nephrol; 2022 Dec; 37(12):3117-3126. PubMed ID: 35286456
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for nephrotic syndrome in children.
Iijima K; Sako M; Nozu K
Clin Exp Nephrol; 2017 Apr; 21(2):193-202. PubMed ID: 27422620
[TBL] [Abstract][Full Text] [Related]
19. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
[TBL] [Abstract][Full Text] [Related]
20. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
